TQD Survey Finds Pharma To Become QC’s Biggest Benefactor


TQD Survey Finds Pharma To Become QC’s Biggest Benefactor

Photo by Hush Naidoo on Unsplash

The Quantum Technologies Survey

Although it is too early to know which business sectors will see the most benefit from the advent of quantum information science and quantum computing (QC) in the years to come, the pharmaceutical industry is a prime candidate. Quantum information science can, with enough investment, seriously speed up, improve and save money for that industry. This could revolutionize processes within biopharma R&D where, currently, a new drug can take over a decade to produce from its initial discovery, clinical trails to it hitting the pharmacy shelves — and this is even with the help of powerful supercomputers that can achieve extraordinary parallel processing. With all that assistance, the drug — which could have cost billions to develop — is not a guaranteed moneymaker. That is why risk-averse pharmaceutical companies count on only a few drugs to be profitable, acting as a counterbalance to all the duds they manufacture.

In the times of the COVID-19 pandemic, it would be great for those companies and we the public as clients to avoid such things altogether.

And the manipulation of qubits could just be the solution.

If, in fact, the pharmaceutical industry will be the likeliest industry to benefit from quantum computing and quantum information science, it can only be good for humankind. But, usually, conjecture abounds. Opinions split, at least in the mass media where science is little understood. At TQD, though, we take quantum seriously, and because we want to shed light on this we have published The Quantum Technologies Survey. The methodology behind the survey was to investigate the community’s opinion on key quantum computing milestones (e.g. practical quantum advantage), use cases and investment in the space. Based on the data from 35 anonymous respondents from a range of backgrounds that includes CEOs, senior researchers and a quantum lead at a large corporation within the QC industry, the results were interesting but in line with the general consensus.


Chemistry/Pharma (e.g. protein folding) came up on top, with security (e.g. cybersecurity) as runner up. In last place (of six sector categories) was industry (e.g. aerospace design), with tech, finance and energy placing in the middling crowd.

For more data on this and other key areas in QC that include investment, commercialization, people in the industry, and quantum ethics, head on over to TQD website and The Quantum Technologies Survey.

Want an even greater in-depth walk to all things QC, quantum information science and quantum tech? Easy, just sign up for TQD’s extensive beta version dataset where registered users can get access to a subset of our database for free (covering quantum technology organizations and investors).*

We are living in extraordinary times. Quantum, no doubt, will make it even more extraordinary. TQD wants to be there as it happens, with you, of course, by our side.

*For full access to our proprietary database, please contact us at hello@thequantuminsider.com.

James Dargan

James Dargan

James Dargan is a writer and researcher at The Quantum Insider. His focus is on the QC startup ecosystem and he writes articles on the space that have a tone accessible to the average reader.

Share This Article

The Quantum Insider
Explore our intelligence solutions

Join Our Newsletter